# A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

> **NCT06891560** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 34 (estimated)

## Conditions studied

- Adenoid Cystic Carcinoma

## Interventions

- **DRUG:** Enfortumab Vedotin

## Key facts

- **NCT ID:** NCT06891560
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06891560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06891560, "A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06891560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*